Alzamend Neuro (ALZN US): Synthetic Expert Call Transcript (24 Aug 2026)
AL001's clinical thesis rests entirely on its 505(b)(2) regulatory pathway and head-to-head brain imaging bioequivalence. By utilizing a patented...
87 Views
IPO Databook: Alzamend Neuro (ALZN US) - Aug 2026
Alzamend Neuro, Inc. develops novel therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress...
91 Views
No more insights